Effect of Statins on Collagen Type I Degradation in Patients With Coronary Artery Disease and Atrial Fibrillation

American Journal of Cardiology

Volumn 101, Issue 2, 2008, Pages 199-202

  Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Stakos, Dimitrios A ^a   Papanas, Nikolaos ^a   Chatzikyriakou, Sofia V ^a   Mitrousi, Konstantina ^a   Maltezos, Efstratios ^a   Boudoulas, Harissios ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; CLOPIDOGREL; COLLAGEN TYPE 1; CREATININE; DICOUMAROL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

AGED; ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; COLLAGEN TYPE I; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; TREATMENT OUTCOME;

EID: 37549053629     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.063     Document Type: Article

References (19)

1. Young-Xu Y., Jabbour S., Goldberg R., Blatt C.M., Graboys T., BilchiK B., and Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
2. Marin F., Pascual D.A., Roldan V., Arribas J.M., Ahumada M., Tornel P.L., Oliver C., Gomez-Plana J., Lip G.Y.H., and Valdes M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97 (2006) 55-60
3. Amar D., Zhang H., Heerdt P.M., Park B., Fleisher M., and Thaler H.T. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128 (2005) 3421-3427
4. Patti G., Chello M., Candura D., Pasceri V., D' Ambrosio A., Covino E., and Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study. Circulation 114 (2006) 1455-1461
5. Allessie M., Ausma J., and Schotten U. Electrical, contractile, and structural remodeling during atrial fibrillation. Cardiovasc Res 54 (2002) 230-246
6. Kostin S., Klein G., Szalay Z., Hein S., Bauer E.P., and Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54 (2002) 361-379
7. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13 (1989) 1637-1652
8. McNamara R.L., Brass L.M., Drozda Jr. J.P., Go A.S., Halperin J.L., Kerr C.R., Levy S., Malenka D.J., Mittal S., Pelosi Jr. F., et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol 44 (2004) 475-495
9. Cannon C.P., Battler A., Brindis R.G., Cox J.L., Ellis S.G., Every N.R., Flaherty J.T., Harrington R.A., Krumholz H.M., Simoons M.L., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 38 (2001) 2114-2130
10. Cheitlin M.D., Alpert J.S., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davidson T.W., Davis J.L., Douglas P.S., and Gillam L.D. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation 95 (1997) 1686-1744
11. Boos C.J., Andreson R.A., and Lip G.Y.H. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 27 (2006) 136-149
12. Kumagai K., Nakashima H., and Seku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 (2004) 105-111
13. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., Quinones M.A., Zoghbi W.A., Entman M.L., Roberts R., and Marian A.J. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophied cardiomyopathy. Circulation 104 (2001) 317-324
14. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
15. Zhang J., Cheng X., Liao Y.H., Lu B., Yang Y., Li B., Ge H., Wang M., Liu Y., Guo Z., and Zhang L. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 19 (2005) 13-21
16. Chen J., and Mehta J.L. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291 (2006) 1738-1745
17. Martin J., Denver R., Bailey M., and Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 32 (2005) 697-701
18. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., and Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 (1998) 2433-2444
19. Ruiz-Gaspa S., Nogues X., Enjuanes A., Monllau J.C., Blanch J., Carreras R., Mellibovsky L., Grinberg D., Balcells S., Díez-Perez A., and Pedro-Botet J. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Biol Chem 101 (2007) 1430-1438